Evidence map›Paper›PMID 41800083›Full record

ArticleFrontiers in pharmacology2026

Globulol from

Zhe Wang, Yinghong Zhong, Jicheng Hu, Peishi Xie, Yuan Zhao, Cunzhen Jiang, Lu Lu, Mingyan Zhou, Jian Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhe Wang *Hepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Yinghong Zhong *Hepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Jicheng Hu *Hepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Peishi Xie *Hepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Yuan ZhaoHepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Cunzhen JiangHepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Lu LuDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Mingyan ZhouInstitute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Jian XuHepatobiliary and Liver Transplantation Department of Hainan Digestive Disease Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Globulol is a terpenoid metabolite isolated from Materials and Methods: The influence of Globulol on HCC cell lines was assessed Results: Globulol notably decreased the viability of Huh1/Huh7 cells in a concentration-dependent manner. It was found to prompt the secretion of the chemokine CCL4 by tumor cells, enhancing the infiltration of cytotoxic CD8 Conclusion: These results suggest that Globulol can promote a microenvironment permissive to PD-1 blockade, thereby exerting anti-HCC activity. Hence, the combination of Globulol and PD-1 blockade may be a promising strategy for HCC treatment.

Indexed as

Alpinia oxyphylla Miq.anti-PD-1 drugsglobulolhepatocellular carcinomaPD-L1tislelizumab

Identifiers

PMID41800083
PMCPMC12963335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.